Ignite Creation Date:
2024-05-06 @ 8:20 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06343064
Status:
RECRUITING
Last Update Posted:
2024-04-02
First Post:
2024-03-21
Brief Title:
Vebreltinib Plus PLB1004 in EGFR-mutated Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
Sponsor:
Avistone Biotechnology Co Ltd
Organization:
Avistone Biotechnology Co Ltd
Study Overview
Official Title:
A Phase IbII Study of Vebreltinib Plus PLB1004 in EGFR-mutated Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 in EGFR TKI Relapsed MET Amplified or MET Expression in NSCLC
Detailed Description:
Open label multicenter Phase IbII clinical study to evaluate the safety efficacy and pharmacokinetics of Vebreltinib in combination with PLB1004 in patients with locally advanced or metastatic non-small cell lung cancer with MET overexpression or MET amplification following EGFR-TKI treatment failure
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None